Blocking effects on Orai channels (204 Li et al., 2019);Inhibition of CYP3A cytochrome (205 Foti et al., 2011); inhibition of Kv10.1 (206 Gómez-Lagunas et al., 2017)In a phase I clinical trial for the treatment of gliomas. The gene discussed is CYP3A4; the disease is central nervous system cancer.